>>The Sanofi/GSK one's still delayed but not sure how long (some say Feb some say end of year)
A few interesting things here. Firstly they are re-doing Phase 2 of trials with a new formulation to try to increase the concentration of the antigen caused. Whilst the vaccine worked, it's effect was too weak to prevent significant amounts of infection.
Earliest is EOY/21 assuming no further difficulties.
The EU has ordered 300 million doses of this vaccine which they had originally envisaged receiving late Q1/21 after approval Jan/Feb 21 hence their reduced ability to deal with slower delivery schedules from other vaccines.
The confusing statements & dates are probably caused by the fact that Sanofi is developing two different approaches, the second of which would have been considerably behind the first, were it not for the delay to the first. They now overlap.
My guess would be that GSK accept that they have missed the original world-saving impact and are now looking at developing a stable, easy to store, easy to deliver vaccine believing that long-haul adaptable vaccines will be required.
|